Galecto (GLTO)
Preclinical biotech targeting mutant calreticulin blood disorders.
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Galecto, Inc. (NASDAQ: GLTO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and two
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February
Galecto, Inc. (NASDAQ: GLTO - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 277,004 shares, a growth of 86.6% from the January 29th total of 148,474 shares. Approximately 19.4% of the company's stock are short sold. Based
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,171,052 additional shares, at a public offering price of $19.00 per share. The aggregate gross proceeds to Galecto from the offering were approximately $316.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto.
Galecto Announces Pricing of $275 Million Underwritten Public Offering
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expected to be approximately $275 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto and assuming no exercise of the underwriters' option to purchase additional shares.
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts
Shares of Galecto, Inc. (NASDAQ: GLTO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one
Analysts Set Galecto, Inc. (NASDAQ:GLTO) PT at $41.00
Galecto, Inc. (NASDAQ: GLTO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has assigned a
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA)
Avidity Biosciences (NASDAQ: RNA - Get Free Report) and Galecto (NASDAQ: GLTO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk. Risk and Volatility Avidity Biosciences has a beta of
Galecto (NASDAQ:GLTO) Shares Down 13.3% – Time to Sell?
Galecto, Inc. (NASDAQ: GLTO - Get Free Report)'s stock price dropped 13.3% on Monday. The stock traded as low as $29.61 and last traded at $29.61. Approximately 82,189 shares changed hands during trading, a decline of 29% from the average daily volume of 116,104 shares. The stock had previously closed at $34.14. Analyst Upgrades and
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company's Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the Company's common stock to one new employee (the “Inducement Grant”) on December 15, 2025 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company's 2022 Inducement Plan, as amended from time to time.
GLTO, MOVE: two penny stocks quadrupled today – but should you buy?
Two obscure US biotech and medtech names – Galecto Inc (NASDAQ: GLTO) and Movano Inc (NASDAQ: MOVE) – stunned markets today with explosive rallies, each surging roughly 300%. While the gains were triggered by company-specific news, the magnitude of the moves has drawn speculative interest from retail traders and momentum chasers.
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029
Galecto Inc. (NASDAQ:GLTO) stock tripled on Monday, with a session volume of 23.26 million, compared to the average volume of 2.41 million, as per data from Benzinga Pro.
Galecto Announces Acquisition of Damora Therapeutics
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms
Galecto Reports Third Quarter 2025 Operating and Financial Results
BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, today announced its operating and financial results for the quarter ended September 30, 2025.
What's Going On With Nano-Cap Galecto Stock On Tuesday?
Galecto Inc. (NASDAQ:GLTO) stock spiked on Tuesday, with a session volume of 61.11 million, compared to the average volume of 984,320, as per data from Benzinga Pro.
Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble
Galecto stock (NASDAQ: GLTO) went absolutely bonkers on Tuesday, surging over 600% in what might be one of the wildest rallies we have seen from a small biotech in recent memory. The shares jumped from a close of $3.71 the day before to an intraday high around $25.99, fueled by a massive pre-market buying spree.
Galecto Reports Second Quarter 2025 Operating and Financial Results
BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended June 30, 2025.
12,701 Shares in Galecto, Inc. (NASDAQ:GLTO) Bought by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new position in shares of Galecto, Inc. (NASDAQ:GLTO – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,701 shares of the company’s stock, valued at approximately $59,000. Squarepoint Ops LLC owned approximately 0.96% of Galecto at the end of the most recent quarter. Galecto Trading Up 2.1% Shares of GLTO stock opened at $3.36 on Wednesday. Galecto, Inc. has a 12 month low of $2.01 and a 12 month high of $16.07. The company has a market cap of $4.44 million, a P/E ratio of -0.18 and a beta of 1.32. The firm has a fifty day moving average price of $2.82 and a 200 day moving average price of $4.13. Galecto (NASDAQ:GLTO – Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.92) earnings per share (EPS) for the quarter. On average, equities analysts forecast that Galecto, Inc. will post -15.91 EPS for the current year. Galecto Profile (Free Report) Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.
Galecto Reports Full-Year 2024 Financial Results
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.